vs

Side-by-side financial comparison of AXCELIS TECHNOLOGIES INC (ACLS) and NovoCure Ltd (NVCR). Click either name above to swap in a different company.

AXCELIS TECHNOLOGIES INC is the larger business by last-quarter revenue ($238.3M vs $174.1M, roughly 1.4× NovoCure Ltd). AXCELIS TECHNOLOGIES INC runs the higher net margin — 14.4% vs -40.9%, a 55.3% gap on every dollar of revenue. On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs -5.6%). Over the past eight quarters, NovoCure Ltd's revenue compounded faster (7.6% CAGR vs -2.8%).

Axcelis Technologies, Inc. is an American company engaging in the design, manufacture, and servicing of capital equipment for the semiconductor manufacturing industry worldwide. It produces ion implantation systems, including high and medium current implanters, and high energy implanters, and curing systems used in the fabrication of semiconductor chips. The company was incorporated in 1995 and is headquartered in Beverly, Massachusetts, United States.

NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.

ACLS vs NVCR — Head-to-Head

Bigger by revenue
ACLS
ACLS
1.4× larger
ACLS
$238.3M
$174.1M
NVCR
Growing faster (revenue YoY)
NVCR
NVCR
+17.9% gap
NVCR
12.3%
-5.6%
ACLS
Higher net margin
ACLS
ACLS
55.3% more per $
ACLS
14.4%
-40.9%
NVCR
Faster 2-yr revenue CAGR
NVCR
NVCR
Annualised
NVCR
7.6%
-2.8%
ACLS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACLS
ACLS
NVCR
NVCR
Revenue
$238.3M
$174.1M
Net Profit
$34.3M
$-71.1M
Gross Margin
47.0%
77.6%
Operating Margin
15.2%
Net Margin
14.4%
-40.9%
Revenue YoY
-5.6%
12.3%
Net Profit YoY
-31.3%
-107.3%
EPS (diluted)
$1.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLS
ACLS
NVCR
NVCR
Q1 26
$174.1M
Q4 25
$238.3M
$174.3M
Q3 25
$213.6M
$167.2M
Q2 25
$194.5M
$158.8M
Q1 25
$192.6M
$155.0M
Q4 24
$252.4M
$161.3M
Q3 24
$256.6M
$155.1M
Q2 24
$256.5M
$150.4M
Net Profit
ACLS
ACLS
NVCR
NVCR
Q1 26
$-71.1M
Q4 25
$34.3M
$-24.5M
Q3 25
$26.0M
$-37.3M
Q2 25
$31.4M
$-40.1M
Q1 25
$28.6M
$-34.3M
Q4 24
$50.0M
$-65.9M
Q3 24
$48.6M
$-30.6M
Q2 24
$50.9M
$-33.4M
Gross Margin
ACLS
ACLS
NVCR
NVCR
Q1 26
77.6%
Q4 25
47.0%
75.8%
Q3 25
41.6%
73.2%
Q2 25
44.9%
73.9%
Q1 25
46.1%
75.1%
Q4 24
46.0%
79.2%
Q3 24
42.9%
77.2%
Q2 24
43.8%
77.0%
Operating Margin
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
15.2%
-23.2%
Q3 25
11.7%
-21.5%
Q2 25
14.9%
-24.9%
Q1 25
15.1%
-24.4%
Q4 24
21.6%
-39.3%
Q3 24
18.3%
-20.7%
Q2 24
20.6%
-22.3%
Net Margin
ACLS
ACLS
NVCR
NVCR
Q1 26
-40.9%
Q4 25
14.4%
-14.1%
Q3 25
12.2%
-22.3%
Q2 25
16.1%
-25.3%
Q1 25
14.8%
-22.1%
Q4 24
19.8%
-40.9%
Q3 24
18.9%
-19.7%
Q2 24
19.8%
-22.2%
EPS (diluted)
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
$1.11
$-0.22
Q3 25
$0.83
$-0.33
Q2 25
$0.98
$-0.36
Q1 25
$0.88
$-0.31
Q4 24
$1.54
$-0.61
Q3 24
$1.49
$-0.28
Q2 24
$1.55
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLS
ACLS
NVCR
NVCR
Cash + ST InvestmentsLiquidity on hand
$374.3M
$432.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.0B
$330.7M
Total Assets
$1.4B
$787.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLS
ACLS
NVCR
NVCR
Q1 26
$432.0M
Q4 25
$374.3M
$93.5M
Q3 25
$449.6M
$342.1M
Q2 25
$549.8M
$149.6M
Q1 25
$587.1M
$127.3M
Q4 24
$571.3M
$163.8M
Q3 24
$579.4M
$185.4M
Q2 24
$548.3M
$164.8M
Stockholders' Equity
ACLS
ACLS
NVCR
NVCR
Q1 26
$330.7M
Q4 25
$1.0B
$340.5M
Q3 25
$1.0B
$341.3M
Q2 25
$1.0B
$349.4M
Q1 25
$1.0B
$362.0M
Q4 24
$1.0B
$360.2M
Q3 24
$975.6M
$360.8M
Q2 24
$934.9M
$361.8M
Total Assets
ACLS
ACLS
NVCR
NVCR
Q1 26
$787.9M
Q4 25
$1.4B
$804.3M
Q3 25
$1.4B
$1.4B
Q2 25
$1.3B
$1.2B
Q1 25
$1.3B
$1.2B
Q4 24
$1.3B
$1.2B
Q3 24
$1.3B
$1.2B
Q2 24
$1.3B
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLS
ACLS
NVCR
NVCR
Operating Cash FlowLast quarter
$-6.6M
Free Cash FlowOCF − Capex
$-8.9M
FCF MarginFCF / Revenue
-3.7%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$107.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
$-6.6M
$-18.0M
Q3 25
$45.4M
$20.6M
Q2 25
$39.7M
$-15.9M
Q1 25
$39.8M
$-35.7M
Q4 24
$12.8M
$-3.5M
Q3 24
$45.7M
$10.4M
Q2 24
$40.1M
$-1.7M
Free Cash Flow
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
$-8.9M
$-22.9M
Q3 25
$43.3M
$14.9M
Q2 25
$37.7M
$-21.4M
Q1 25
$34.8M
$-46.3M
Q4 24
$8.1M
$-12.4M
Q3 24
$41.8M
$-307.0K
Q2 24
$38.1M
$-13.2M
FCF Margin
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
-3.7%
-13.1%
Q3 25
20.3%
8.9%
Q2 25
19.4%
-13.5%
Q1 25
18.1%
-29.9%
Q4 24
3.2%
-7.7%
Q3 24
16.3%
-0.2%
Q2 24
14.8%
-8.8%
Capex Intensity
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
1.0%
2.8%
Q3 25
0.9%
3.4%
Q2 25
1.0%
3.5%
Q1 25
2.6%
6.8%
Q4 24
1.8%
5.5%
Q3 24
1.5%
6.9%
Q2 24
0.8%
7.6%
Cash Conversion
ACLS
ACLS
NVCR
NVCR
Q1 26
Q4 25
-0.19×
Q3 25
1.75×
Q2 25
1.27×
Q1 25
1.39×
Q4 24
0.26×
Q3 24
0.94×
Q2 24
0.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACLS
ACLS

Products$224.6M94%
Services$13.7M6%

NVCR
NVCR

Segment breakdown not available.

Related Comparisons